The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Mar. 30, 1:45 AM

Slide #25. Esperion Therapeutics, Inc. Secondary Offering

Company: Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Date announced: 3/17/2015
Shares Offered: 1,750,000
Date of Pricing: 3/18/2015
Price Per Share: $100.00
Secondary Offering Details: Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $22.5 million of additional shares of its common stock. - updated 3/18 - Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the pricing of an underwritten public offering of 1,750,000 shares of its common stock, offered at a price to the public of $100.00 per share. The gross proceeds from this offering to Esperion are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion. Esperion has granted the underwriters a 30-day option to purchase up to an additional 262,500 shares of its common stock. The offering is expected to close on or about March 24, 2015, subject to customary closing conditions. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to complete the clinical development of ETC-1002, including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.

Esperion Therapeutics a clinical stage biopharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Co.'s primary product candidate, is an orally available, once-daily small molecule designed to lower LDL-C levels and avoid the side effects associated with other LDL-C lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-C. ESP41091, Co.'s second product candidate is a pre-IND compound.
Open the ESPR Page at The Online Investor »

Company Name:  Esperion Therapeutics Inc (New)
Website:  www.esperion.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ESPR:  13
Total Market Value Held by ETFs:  $19.99M
Total Market Capitalization:  $1.78B
% of Market Cap. Held by ETFs:  1.12%
 

Open the ESPR Page at The Online Investor (in a new window) »

March 30, 2015    1:45 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.67 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.